Vapaliximab
Vapaliximab is an experimental drug currently under development for the treatment of various cancer types. It is a monoclonal antibody that targets the glycoprotein CD47, a protein often overexpressed on the surface of cancer cells.
Mechanism of Action[edit]
Vapaliximab works by binding to CD47, a protein that is often overexpressed on the surface of cancer cells. CD47 acts as a "don't eat me" signal, preventing the body's immune system from attacking the cancer cells. By binding to CD47, Vapaliximab blocks this signal, allowing the immune system to recognize and destroy the cancer cells.
Clinical Trials[edit]
Vapaliximab is currently in clinical trials for the treatment of various types of cancer. These trials aim to determine the safety, efficacy, and optimal dosage of the drug.
Potential Applications[edit]
If successful in clinical trials, Vapaliximab could be used to treat a wide range of cancers, including leukemia, lymphoma, and solid tumors.
See Also[edit]
References[edit]
<references />
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
